| 1 |
中国医师协会器官移植医师分会, 中华医学会器官移植学分会肝移植学组.中国肝癌肝移植临床实践指南(2021 版)[J/CD].中华移植杂志:电子版,2021,15(6):321-328.
|
| 2 |
Ling S, Jiang G, Que Q, et al.Liver transplantation in patients with liver failure: twenty years of experience from China[J].Liver Int,2022,42(9):2110-2116.
|
| 3 |
Kwong AJ, Kim WR, Lake JR, et al.OPTN/SRTR 2022 Annual Data Report: Liver[J].Am J Transplant, 2024, 24(2s1): S176-S265.
|
| 4 |
Mugaanyi J, Tong J, Lu C, et al.Risk factors for acute rejection in liver transplantation and its impact on the outcomes of recipients[J].Transpl Immunol,2023,76:101767.
|
| 5 |
Zhou J, Wei Q,Zheng S,et al.Early allograft dysfunction after liver transplantation with donation after cardiac death donors [ J].Hepatobiliary Surg Nutr,2019,8(5):566-568.
|
| 6 |
Kim JM, Kim DG, Kim J, et al.Outcomes after liver transplantation in Korea: incidence and risk factors from Korean transplantation registry[J].Clin Mol Hepatol,2021,27(3):451-462.
|
| 7 |
Nemes B, Gaman G, Polak WG, et al.Extended-criteria donors in liver transplantation Part II: reviewing the impact of extended-criteria donors on the complications and outcomes of liver transplantation[J].Expert Rev Gastroenterol Hepatol,2016,10(7):841-859.
|
| 8 |
Nair A, Hashimoto K.Extended criteria donors in liver transplantation - from marginality to mainstream[J].Hepatobiliary Surg Nutr,2018,7(5):386-388.
|
| 9 |
Mohty M.Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond[J].Leukemia,2007,21(7):1387-1394.
|
| 10 |
Montenovo MI, Jalikis FG, Li M, et al.Superior patient and graft survival in adult liver transplant with rabbit antithymocyte globulin induction: experience with 595 patients[J].Exp Clin Transplant,2017,15(4):425-431.
|
| 11 |
Woodruff MF, Anderson NA.Effect of lymphocyte depletion by thoracic duct fistula and administration of antilymphocytic serum on the survival of skin homografts in rats[J].Nature,1963,200:702.
|
| 12 |
Starzl TE, Groth CG, Brettschneider L, et al.Orthotopic homotransplantation of the human liver[J].Ann Surg, 1968, 168(3):392-415.
|
| 13 |
Gharekhani A, Entezari-Maleki T, Dashti-Khavidaki S, et al.A review on comparing two commonly used rabbit anti-thymocyte globulins as induction therapy in solid organ transplantation[J].Expert Opin Biol Ther,2013,13(9):1299-1313.
|
| 14 |
Padiyar A, Augustine JJ, Hricik DE.Induction antibody therapy in kidney transplantation[J].Am J Kidney Dis, 2009, 54(5): 935-944.
|
| 15 |
Bonnefoy-Berard N, Vincent C, Revillard JP.Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins [J].Transplantation, 1991, 51(3):669-673.
|
| 16 |
马葵芬, 朱雪娟, 吴寅, 等.抗体诱导治疗在肝移植中的应用进展[J/CD].中华移植杂志:电子版,2018,12(2):80-85.
|
| 17 |
Cillo U, Bechstein WO, Berlakovich G, et al.Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression[J].Transplant Rev (Orlando), 2018, 32(3):142-150.
|
| 18 |
Hawksworth JS, Leeser D, Jindal RM, et al.New directions for induction immunosuppression strategy in solid organ transplantation[J].Am J Surg,2009,197(4):515-524.
|
| 19 |
Best LM,Leung J,Freeman SC,et al.Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis[J].Cochrane Database Syst Rev,2020,1(1): CD013203.
|
| 20 |
Cai J, Terasaki PI.Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data[J].Transplantation,2010,90(12):1511-1515.
|
| 21 |
Turner AP, Knechtle SJ.Induction immunosuppression in liver transplantation: a review[J].Transpl Int,2013,26(7):673-683.
|
| 22 |
Petite SE, Bollinger JE, Eghtesad B.Antithymocyte globulin induction therapy in liver transplant: old drug, new uses[J].Ann Pharmacother,2016,50(7):592-598.
|
| 23 |
Tchervenkov JI, Tzimas GN, Cantarovich M, et al.The impact of thymoglobulin on renal function and calcineurin inhibitor initiation in recipients of orthotopic liver transplant:a retrospective analysis of 298 consecutive patients[J].Transplant Proc, 2004, 36(6): 1747-1752.
|
| 24 |
高伟东, 杨龙龙, 尹清臣.氧化应激反应在边缘供肝肝移植缺血-再灌注损伤中的作用研究进展[J].器官移植,2022,13(1):126-131.
|
| 25 |
Martin JD, Cabral H, Stylianopoulos T, et al.Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges[J].Nat Rev Clin Oncol,2020,17(4):251-266.
|
| 26 |
Fisher J, Zeitouni N, Fan W, et al.Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review[J].J Am Acad Dermatol, 2020, 82(6): 1490-1500.
|
| 27 |
Helmick RA, Eymard CM, Naik S, et al.A report of a prospective randomized trial of extended-release tacrolimus versus immediate release tacrolimus after liver transplantation with anti-thymocyte induction in a steroid free protocol[J].Clin Transplant, 2024, 38(1): e15172.
|
| 28 |
Rodriguez-Peralvarez M, Germani G, Papastergiou V, et al.Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome [J].J Hepatol,2013,58(2):262-270.
|
| 29 |
Soliman T, Hetz H, Burghuber C, et al.Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation [J].Liver Transpl,2007,13(7):1039-1044.
|
| 30 |
Eason JD, Nair S, Cohen AJ, et al.Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy[J].Transplantation,2003,75(8):1396-1399.
|
| 31 |
Martin SP, Mehta N, Emamaullee J.Immune checkpoint inhibitors in liver transplantation: Current practice, challenges, and opportunities[J].Liver Transpl,2024,30(7):742-752.
|
| 32 |
Tabrizian P, Abdelrahim M, Schwartz M.Immunotherapy and transplantation for hepatocellular carcinoma[J].J Hepatol,2024,80(5):822-825.
|
| 33 |
Jadlowiec CC, Taner T.Liver transplantation: Current status and challenges[J].World J Gastroenterol,2016,22(18):4438-4445.
|
| 34 |
Llovet JM, Castet F, Heikenwalder M, et al.Immunotherapies for hepatocellular carcinoma[J].Nat Rev Clin Oncol, 2022, 19(3):151-172.
|
| 35 |
Pinter M, Scheiner B, Pinato DJ.Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice[J].Lancet Gastroenterol Hepatol,2023,8(8):760-770.
|
| 36 |
Schnickel GT, Fabbri K, Hosseini M, et al.Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab[J].Am J Transplant,2022,22(6):1699-1704.
|
| 37 |
中华医学会器官移植学分会.器官移植免疫抑制剂临床应用技术规范(2019 版)[J].器官移植,2019,10(3):213-226.
|
| 38 |
Halldorson JB, Bakthavatsalam R, Montenovo M, et al.Differential rates of ischemic cholangiopathy and graft survival associated with induction therapy in DCD liver transplantation[J].Am J Transplant,2015,15(1):251-258.
|
| 39 |
Liu J, Man K.Mechanistic insight and clinical implications of ischemia/reperfusion injury post liver transplantation[J].Cell Mol Gastroenterol Hepatol,2023,15(6):1463-1474.
|
| 40 |
Ito T, Naini BV,Markovic D,et al.Ischemia-reperfusion injury and its relationship with early allograft dysfunction in liver transplant patients[J].Am J Transplant,2021,21(2):614-625.
|
| 41 |
Bogetti D, Sankary HN, Jarzembowski TM, et al.Thymoglobulin induction protects liver allografts from ischemia/reperfusion injury[J].Clin Transplant,2005,19(4):507-511.
|
| 42 |
Guirado L.Does rabbit antithymocyte globulin (thymoglobuline® )have a role in avoiding delayed graft function in the modern era of kidney transplantation?[J].J Transplant,2018,2018:4524837.
|
| 43 |
Angeli P, Garcia-Tsao G, Nadim MK, et al.News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA)consensus document[J].J Hepatol,2019,71(4):811-822.
|
| 44 |
Parajuli S, Foley D, Djamali A, et al.Renal function and transplantation in liver disease[J].Transplantation, 2015, 99(9):1756-1764.
|
| 45 |
Hussaini T, Yoshida EM, Partovi N, et al.Early persistent progressive acute kidney injury and graft failure post liver transplantation[J].Transplant Direct,2019,5(3): e429.
|
| 46 |
中华医学会器官移植学分会,中国医师协会器官移植医师分会.中国肝移植受者肾损伤管理临床实践指南(2023 版)[J/CD].中华移植杂志:电子版,2023,17(6):321-331.
|
| 47 |
Raja K, Panackel C.Post Liver transplant renal dysfunctionevaluation, management and immunosuppressive practice[J].J Clin Exp Hepatol,2024,14(2):101306.
|
| 48 |
Zhou J, Zhang X, Lyu L, et al.Modifiable risk factors of acute kidney injury after liver transplantation: a systematic review and meta-analysis[J].BMC Nephrol,2021,22(1):149.
|
| 49 |
Nair A, Coromina Hernandez L, Shah S, et al.Induction therapy with antithymocyte globulin and delayed calcineurin inhibitor initiation for renal protection in liver transplantation: a multicenter randomized controlled phase Ⅱ-b trial[J].Transplantation, 2022,106(5):997-1003.
|
| 50 |
Bajjoka I, Hsaiky L, Brown K, et al.Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors[J].Liver Transpl, 2008,14(1):66-72.
|
| 51 |
Razonable RR.Cytomegalovirus infection after liver transplantation:current concepts and challenges[J].World J Gastroenterol, 2008,14(31):4849-4860.
|
| 52 |
Sampathkumar P, Paya CV.Management of cytomegalovirus infection after liver transplantation[J].Liver Transpl, 2000, 6(2): 144-156.
|
| 53 |
Masetti M, Montalti R, Arpinati M, et al.High dose rabbit antithymocyte globulin induction in living related liver transplantation[J].Hepatogastroenterology,2007,54(75):884-888.
|
| 54 |
Kamar N, Borde JS, Sandres-Saune K, et al.Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C[J].Clin Transplant,2005,19(1):83-89.
|
| 55 |
Joshi D, Pinzani M, Carey I, et al.Recurrent HCV after liver transplantation-mechanisms, assessment and therapy[J].Nat Rev Gastroenterol Hepatol,2014,11(12):710-721.
|
| 56 |
Howell J, Angus P, Gow P.Hepatitis C recurrence: the Achilles heel of liver transplantation[J].Transpl Infect Dis, 2014, 16(1):1-16.
|
| 57 |
Fagiuoli S, Ravasio R, Luca MG, et al.Management of hepatitis C infection before and after liver transplantation [ J].World J Gastroenterol,2015,21(15):4447-4456.
|
| 58 |
Vivarelli M, Burra P, La Barba G, et al.Influence of steroids on HCV recurrence after liver transplantation: a prospective study[J].J Hepatol,2007,47(6):793-798.
|
| 59 |
Samonakis DN, Germani G, Burroughs AK.Immunosuppression and HCV recurrence after liver transplantation[J].J Hepatol, 2012, 56(4):973-983.
|
| 60 |
Nair S, Loss GE, Cohen AJ, et al.Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection[J].Transplantation,2006,81(4):620-622.
|
| 61 |
Zhang Z, Sun J, Guo M, et al.Progress of new-onset diabetes after liver and kidney transplantation[J].Front Endocrinol (Lausanne),2023,14:1091843.
|
| 62 |
Ling Q, Xu X, Xie H, et al.New-onset diabetes after liver transplantation:a national report from China Liver Transplant Registry[J].Liver Int,2016,36(5):705-712.
|
| 63 |
Lv C, Zhang Y, Chen X, et al.New-onset diabetes after liver transplantation and its impact on complications and patient survival[J].J Diabetes,2015,7(6):881-890.
|
| 64 |
Trinanes J, Rodriguez-Rodriguez AE, Brito-Casillas Y, et al.Deciphering tacrolimus-induced toxicity in pancreatic beta cells[J].Am J Transplant,2017,17(11):2829-2840.
|
| 65 |
Chevallier E, Jouve T, Rostaing L, et al.Pre-existing diabetes and PTDM in kidney transplant recipients: how to handle immunosuppression[J].Expert Rev Clin Pharmacol,2021,14(1):55-66.
|
| 66 |
Charlton M, Levitsky J, Aqel B, et al.International liver transplantation society consensus statement on immunosuppression in liver transplant recipients[J].Transplantation,2018,102(5):727-743.
|
| 67 |
中华医学会器官移植学分会.中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019 版) [J/CD].中华移植杂志:电子版,2019,13(4):262-268.
|
| 68 |
张晋平, 朱志军, 孙丽莹, 等.抗胸腺细胞球蛋白治疗肝移植术后耐激素急性排斥反应1 例报告并文献复习[J].精准医学杂志,2022,37(5):396-399,403.
|
| 69 |
Lee JG, Lee J, Lee JJ, et al.Efficacy of rabbit anti-thymocyte globulin for steroid-resistant acute rejection after liver transplantation[J].Medicine (Baltimore),2016,95(23): e3711.
|
| 70 |
Schmitt TM, Phillips M, Sawyer RG, et al.Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation[J].Dig Dis Sci,2010,55(11):3224-3234.
|
| 71 |
Bijleveld CG, Klompmaker IJ, Van Den Berg AP, et al.Incidence,risk factors, and outcome of antithymocyte globulin treatment of steroid-resistant rejection after liver transplantation[J].Transpl Int,1996,9(6):570-575.
|
| 72 |
Palmer WC, Taner CB, Keaveny AP, et al.Antithymocyte globulin use for corticosteroid nonresponsive rejection after kiver rransplantation[J].Transplant Proc,2018,50(10):3606-3614.
|
| 73 |
Soleimanpour SA, Sekiguchi DR, Larosa DF, et al.Hypersensitivity to rabbit antithymocyte globulin in an islet transplant recipient:a case report[J].Transplant Proc,2011,43(9):3302-3306.
|
| 74 |
De Pietri L, Serra V, Preziosi G, et al.Perioperative effects of high doses of intraoperative thymoglobulin induction in liver transplantation[J].World J Transplant,2015,5(4):320-328.
|
| 75 |
Sevrin F, Gonzales F, Machuron F, et al.Antithymocyte globulin in pediatric allogeneic hematopoietic stem cell transplantation: Infusion time and tolerability [J].Pediatr Transplant, 2020, 24 (4):e13694.
|
| 76 |
褚静茹, 杨滢, 刘育蕾, 等.兔抗人胸腺细胞免疫球蛋白治疗肝移植术后急性排斥的观察与护理[J].天津护理, 2015, 23(6):491-492.
|
| 77 |
Hardinger KL.Rabbit antithymocyte globulin induction therapy in adult renal transplantation[J].Pharmacotherapy, 2006, 26(12):1771-1783.
|
| 78 |
Burkhalter F, Schaub S, Bucher C, et al.A comparison of two types of rabbit antithymocyte globulin induction therapy in immunological high-risk kidney recipients: a prospective randomized control study[J].PLoS One,2016,11(11): e0165233.
|
| 79 |
Furlanetto G, Alegretti AP, Farias MG, et al.Cut-off value for absolute lymphocytes as an alternative for the immunophenotypic analysis of CD3 + T cells in the monitoring of immunosuppressive therapy with thymoglobulin[J].J Bras Nefrol, 2017, 39(2): 181-185.
|
| 80 |
Rasander RO, Sorensen SS, Krohn PS, et al.Interruption of antithymocyte globuline treatment in solid organ transplantation is effectively monitored through a low total lymphocyte count[J].Front Immunol,2024,15:1419726.
|